Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
10 nov. 2022 11h52 HE
|
Biofrontera Inc.
WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will...
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
20 oct. 2022 11h40 HE
|
Biofrontera Inc.
WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
14 oct. 2022 08h40 HE
|
Biofrontera Inc.
WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
29 sept. 2022 10h04 HE
|
Biofrontera Inc.
WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
04 août 2022 08h30 HE
|
Biofrontera Inc.
WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will...
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
01 août 2022 11h00 HE
|
Biofrontera Inc.
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI),...
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
19 mai 2022 09h48 HE
|
Biofrontera Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
13 avr. 2022 10h10 HE
|
Biofrontera Inc.
Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical...
Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022
06 avr. 2022 08h30 HE
|
Biofrontera Inc.
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today...